Lead Product(s) : Pentixafor
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : ELSA Eckert Life Science Accelerator
Deal Size : $16.2 million
Deal Type : Series A Financing
PENTIXAPHARM Secures € 15 Million Series A Financing
Details : Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System Lymphoma.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 06, 2020
Lead Product(s) : Pentixafor
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : ELSA Eckert Life Science Accelerator
Deal Size : $16.2 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?